Trellus Health PLC Notice of Results (3715M)
14 9월 2023 - 3:00PM
UK Regulatory
TIDMTRLS
RNS Number : 3715M
Trellus Health PLC
14 September 2023
Trellus Health plc
("Trellus Health" or the "Company")
Notice of Results
Investor Presentation
LONDON, U.K. AND NEW YORK, U.S. (14 September 2023). Trellus
Health plc (AIM: TRLS), which is commercializing a scientifically
validated and clinically proven personalized resilience-driven
self-management solution for chronic health conditions at their
intersection with mental health, announces that it expects to
report its interim results for the period ended 30 June 2023 on 28
September 2023.
Investor Presentation
Dr. Marla Dubinsky, CEO and Co-Founder, and Joy Bessenger, Chief
Financial Officer, will provide a live presentation relating to the
interim results via Investor Meet Company on 2 October 2023 at
17:00 BST.
The presentation is open to all existing and potential
shareholders. Questions can be submitted pre-event via your
Investor Meet Company dashboard up until 9am the day before the
meeting or at any time during the live presentation.
Investors can sign up to Investor Meet Company for free and add
to meet Trellus Health plc via:
https://www.investormeetcompany.com/trellus-health-plc/register-investor
Investors who already follow Trellus Health plc on the Investor
Meet Company platform will automatically be invited.
For further information please contact:
Trellus Health plc https://trellushealth.com/
Dr. Marla Dubinsky, CEO and Co-Founder Via Walbrook PR
Dr. Daniel Mahony Chairman
Singer Capital Markets (Nominated Tel: +44 (0)20 7496 3000
Adviser and Broker)
Aubrey Powell / Jen Boorer
Walbrook PR Tel: +44 (0)20 7933 8780 or trellus@walbrookpr.com
Paul McManus / Sam Allen / Mob: +44 (0)7980 541 893 / 0 7748 651 727
Phillip Marriage / 07867 984 082
About Trellus Health plc ( www.trellushealth.com )
Trellus Health (LSE: TRLS) is the first resilience-focused
digital health company targeting the intersection of chronic
illness and mental health. Trellus Health integrates its
proprietary resilience-based methodology with the technology,
tools, and expert coaching and educator team to deliver Trellus
Elevate(TM), a whole-person technology-enhanced experience that
empowers individuals to master their health and results in
relieving disease burden, building self-management skills and
promoting positive health behaviours that improves outcomes and
enables thriving in the face of a chronic condition.
The Company was founded by Mount Sinai faculty members Marla C.
Dubinsky, MD and Laurie Keefer, PhD, both experts at treating and
healing both the physical and emotional impacts of IBD and IBS and
have been innovators for whole person healthcare for a combined 50
years.
The Company was initially focused on inflammatory bowel disease
("IBD"), which includes the chronic incurable conditions of Crohn's
Disease and ulcerative colitis but has now added Irritable Bowel
Syndrome ("IBS"). Given the common emotional and mental health
struggles often experienced by individuals suffering from a variety
of chronic conditions, Trellus Health considers its approach to
have potential utility and demand across many conditions.
The Trellus Elevate(TM) program incorporates the GRITT(TM)
methodology and learnings on resilience from clinical research and
practice conducted at the Mount Sinai IBD Center for more than five
years. This proprietary, resilience-driven methodology has been
scientifically validated to demonstrate meaningful improvements in
patient outcomes, 71% reduction in Emergency Department (A&E)
visits, and 94% reduction in unplanned hospitalisations, which the
directors of the Company believe indicates the potential for
significant cost savings for healthcare payers. Patients with IBD
managed with the proprietary resilience methodology also
experienced a 49% reduction in required opioid use and a 73%
reduction in corticosteroid use 12 months following starting the
program which is a major indicator of improved health outcomes(1)
.
Shares in Trellus Health were admitted to trading on AIM in May
2021, under the ticker TRLS. For more information on Trellus
Health, visit: www.trellushealth.com
(1) Source:
https://www.sciencedirect.com/science/article/pii/S1542356521012258
)
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NORQXLFFXKLEBBZ
(END) Dow Jones Newswires
September 14, 2023 02:00 ET (06:00 GMT)
Trellus Health (LSE:TRLS)
과거 데이터 주식 차트
부터 1월(1) 2025 으로 2월(2) 2025
Trellus Health (LSE:TRLS)
과거 데이터 주식 차트
부터 2월(2) 2024 으로 2월(2) 2025
